Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Ctic,rgn,pwrm On Pennytobuck.comPower3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies.
By: Justin Handy PWRM Products - BC-SeraPro™ BC-SeraPro™ was developed and its performance characteristics determined by the Power3 Medical Products Laboratories. BC-SeraPro™ is an ideal diagnostic test to evaluate breast cancer abnormalities found by mammogram or breast examination. Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. BC-SeraPro™ Cancer Test Kit The test would distinguish women who should have a biopsy from those who can safely avoid one. BC-SeraPro™ could detect the disease at a point when treatment is more effective, less expensive, or both. How It Works BC-SeraPro™ is a blood serum test designed to diagnose breast cancer in individuals. The test is based on proteomic technology in which a blood serum sample drawn from a patient will monitor the concentration of each protein biomarker residing in a panel of blood serum protein biomarkers to determine if a patient has breast cancer. The BC-SeraPro™ test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Probability score is ranged from 0.0 to 1.0. http://www.power3medical.com/ RGN, RegeneRx Biopharmaceuticals Inc. RegeneRx Awarded Australian Patent for New TB4 Applications RegeneRx Biopharmaceuticals, Inc. yesterday announced it has received Notice of Acceptance from the Australian patent office for the use of Thymosin beta 4 (T4), its analogues, isoforms and other derivatives in the treatment of infections and inflammatory disorders including colitis, ileitis, gastrointestinal ulcers and gingivitis, among others. The patent expires in 2023. This is one of several patents the Company has been granted in Australia related to its technology and drug candidates. About RegeneRx RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or T4, for tissue and organ protection, repair and regeneration. Currently RegeneRx has three products in clinical development. RGN-352 is an injectable formulation to treat cardiovascular and central nervous system diseases, as well as other medical indications. RegeneRx has successfully completed a Phase 1 clinical trial with RGN-352. RGN-259 is a sterile, preservative- www.regenerx.com CTIC, Cell Therapeutics, Inc. Cell Therapeutics, Inc. Submits Expanded Pediatric Investigation Plan (PIP) This week CTIC announced that it has submitted an expanded Pediatric Investigation Plan (”PIP”) to the European Medicines Agency (”EMEA”), as part of the process for its submission for a Marketing Authorization Application (”MAA”) for pixantrone in the E.U. for the treatment of relapsed or refractory, aggressive non-Hodgkin’ CTI intends to file the MAA later this year. The pediatric program will study pixantrone in pediatric patients aged 6 months to 18 years with the goal of determining the comparative safety and effectiveness of pixantrone compared to doxorubicin in pediatric lymphoid cancers. CTI submitted the original PIP in September 2009. In April 2010, the EMEA Pediatric Committee (the “PDCO”) recommended CTI expand the PIP because of pixantrone’s potential, but unproven, clinical benefit to children in reducing long-term cardiotoxicity associated with current curative therapies. The recommendation from the PDCO came following discussions with CTI about the preclinical and clinical pixantrone data, including PIX301, and the desire to explore the potential benefits pixantrone may offer to children with hematologic cancer. About Cell Therapeutics, Inc Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for the treatment of cancer. It is developing pixantrone, a Phase III single-agent clinical trial product for the treatment of non-Hodgkins lymphoma and various other hematologic malignancies, solid tumors, and immunological disorders; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, esophageal, and non-small cell lung cancer; and brostallicin, a Phase I/II clinical trials product for the treatment of sarcoma. The company has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P. www.CellTherapeutics.com *********************************** For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/ *********************************** THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://pennytobuck.com/ End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
